Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (301)	11/1/2000 4:00:46 PM
From: tom pope	Read Replies (1) \| Respond to of 2243

Rick, as you well know, my biotech background was zilch when I started following these threads a year ago, and remains zilch today. With that disclaimer -- 1. The stock is likely to be under $10 2. It must develop drugs which address large markets 3. It may be a company in which you have tipped your hand elsewhere on SI. TELK fills the bill. It has: An anticancer compound (TLK286) now in human clinical trials that may be effective in a number of common cancers - ovarian, small cell lung and colorectal. A drug, recently awarded a patent by the EPO, that may be useful in indications already approved for Neupogen (TLK199) A drug that enhances the blood glucose lowering effects of insulin - the type II diabetes market. A program with GNSC, recently announced, to develop estrogen receptor based drugs. (All of the above plagiarized from the company's web site.) Seems to me that TELK is pointed in a direction that could open very large markets if any of the above programs is successful.